| scholarly article | Q13442814 |
| P50 | author | Claus G Roehrborn | Q114079291 |
| P2860 | cites work | Molecular genetics of steroid 5 alpha-reductase 2 deficiency | Q24619385 |
| The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study | Q28261198 | ||
| Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia | Q33961645 | ||
| AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations | Q33967073 | ||
| The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group | Q33970656 | ||
| Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial | Q34000933 | ||
| Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial | Q34002418 | ||
| New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States | Q34057824 | ||
| Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism | Q34210049 | ||
| The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group | Q34745427 | ||
| Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance | Q35082700 | ||
| Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia | Q35651301 | ||
| State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. | Q35982334 | ||
| A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder | Q36418714 | ||
| Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. | Q38484327 | ||
| Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial | Q44297418 | ||
| The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia | Q44697461 | ||
| 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery | Q44843124 | ||
| The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy | Q44996397 | ||
| Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder | Q45100348 | ||
| The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group | Q45335490 | ||
| Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder | Q46445226 | ||
| A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia | Q46582638 | ||
| Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study | Q46990092 | ||
| Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. | Q53242720 | ||
| The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. | Q53628573 | ||
| Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. | Q53692984 | ||
| Effects of Acute Treatment With Tamsulosin Versus Alfuzosin on Ejaculatory Function in Normal Volunteers | Q56626146 | ||
| Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting | Q57307267 | ||
| Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries | Q66829208 | ||
| Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia | Q69048813 | ||
| The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia | Q69103966 | ||
| Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? | Q71752227 | ||
| Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia | Q80029142 | ||
| Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia | Q80098730 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostatic hypertrophy | Q506659 |
| P304 | page(s) | 14-25 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Reviews in urology | Q26853801 |
| P1476 | title | Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations | |
| P478 | volume | 10 |
| Q48571117 | Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Early Results |
| Q67223712 | Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia |
| Q94401199 | Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia |
| Q33732687 | Cholesterol and benign prostate disease |
| Q47940544 | Convective Radiofrequency Water Vapor Thermal Therapy with Rezūm System |
| Q36564151 | Current trends in the management of difficult urinary catheterizations |
| Q61455991 | DNA methylation in development and disease: an overview for prostate researchers |
| Q92804136 | Does Prostate Artery Embolization (PAE) Improve Voiding Symptoms, Storage Symptoms, or Both? |
| Q39015782 | Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia |
| Q40246601 | Effect of Transurethral Resection of the Prostate on Storage Symptoms in Patients with Benign Prostatic Hyperplasia of Less than 30 ml. |
| Q38231144 | Evaluation and management of post-transurethral resection of the prostate lower urinary tract symptoms |
| Q52559906 | Follow-up of Temporary Implantable Nitinol Device (TIND) Implantation for the Treatment of BPH: a Systematic Review. |
| Q30373008 | Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies. |
| Q38800899 | L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH. |
| Q41096890 | Medium-term efficacy of the prostatic urethral lift |
| Q57042582 | Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years |
| Q41911507 | Predicting outcome of trial of voiding without catheter in acute urinary retention with intravesical prostatic protrusion |
| Q30987913 | Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis |
| Q38155496 | Serum testosterone level, testosterone replacement treatment, and prostate cancer |
| Q43255237 | Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction |
| Q38901794 | Urolift: a New Face of Minimally Invasive Surgical Technique for Benign Prostatic Hyperplasia? |
Search more.